Abstract
Background: Morbidity, mortality and re- infarction rate are higher following myocardial infarction in diabetics than non-diabetic subjects. Recently, glucagon-like peptide (GLP)-1 was shown to have cardioprotective effects, but treatment with GLP-1 is limited by its short half-life. It is rapidly degraded by the enzyme dipeptidyl peptidase-IV (DPP-IV). We hypothesized that DPP-IV inhibitor Vildagliptin will increase levels of GLP-1 and may confer cardioprotective effects in setting of diabetes beyond its effect on glycemia. Objective: The aim of the present study was to investigate potential cardioprotective effects and mechanisms of Vildagliptin subsequent to isoproterenol induced myocardial infarction in the setting of diabetes. Methods: Diabetes was induced with single dose of Streptozotocin (STZ): 45mg/kg ip and myocardial infarction was produced by administering isoproterenol (ISP): (85mg/kg, sc) to rats 24 and 48 h prior to sacrification (5 th week). After the confirmation of diabetes on 7 th day (Glucose>200mg/dl), Vildagliptin (10 mg/kg) was administered and various parameters like anti-diabetic (Glucose, HbA1c), cardioprotective (CPK-MB, hs-CRP), hypolipidemic (lipid profile, artherogenic potential), antioxidant (MDA) safety {pancreatic function (lipase), liver function (SGPT), kidney function (Creatinine)} and histopathological indices of injury were evaluated in experimental groups. Results : Vildagliptin (10 mg/kg) treatment demonstrated significant antidiabetic as well as myocardial salvaging effects as indicated by restoration of blood glucose, HbA1c and CPK-MB levels compared to Diabetic- ISP Control group. In addition, Vildagliptin favorably modulated the lipid parameters (TC,TG, HDL, LDL), artherogenic index, lipid peroxidation (MDA), Subsequent to ISP challenge, histopathological assessment of heart, pancreas and biochemical indices of injury confirmed the cardioprotective effects of Vildagliptin in setting of diabetes. Conclusion: The present study concluded that Vildagliptin treatment demonstrated myocardial salvaging effects in type II diabetic rats challenged with experimental Myocardial infarction. Keywords: Vildagliptin, Myocardial Infarction, Diabetes,Streptozotocin Isoproterenol
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
